GAPDHP29

Across TCGA pan-cancer cohorts, GAPDHP29 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of GAPDHP29’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where GAPDHP29 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GAPDHP29 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

UCEC, LUSC, and BRCA are the cancer types where GAPDHP29 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GAPDHP29 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	III,IV	+0.383	<.001	6	view →
LUSC	All	All	+0.055	<.001	6	view →
BRCA	Female	II,III,IV	+0.025	.003	6	view →
COAD	All	All	+0.298	<.001	5	view →
KIRP	All	II,III,IV	+0.076	.024	5	view →
KIRC	Male	All	+0.071	<.001	4	view →
HNSC	Male	All	+0.053	.011	4	view →
KICH	Male	III,IV	−0.062	.044	1	view →
STAD	Male	All	+0.030	.041	1	view →
LIHC	All	All	+0.015	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

GAPDHP29–UCEC

Open the UCEC breakdown →